Protection conferred by booster vaccine doses in hospitalized patients with COVID-19 during the SARS-CoV-2 Omicron BA.2 and BA.5 epidemics from 2022 to 2023 in Greece  

作　　者：Helena C.Maltezou Maria N.Gamaletsou Maria Chini Vasileios Petrakis Vasiliki Rapti Theodoros V.Giannouchos Eleni Karantoni Konstantinos Kounouklas Panagiota Stamou Amalia Karapanou Dimitrios Basoulis Andrianna-Chrysovalanto Verykokkou Kyriakos Souliotis Periklis Panagopoulos Dimitrios Hatzigeorgiou Garyfalia Poulakou Konstantinos N.Syrigos Nikolaos V.Sipsas 

机构地区：[1]Directorate of Research,Studies and Documentation,National Public Health Organization,Athens 15123,Greece [2]Pathophysiology Department,Medical School,National and Kapodistrian University of Athens,Athens 11527,Greece [3]Third Department of Internal Medicine and Infectious Diseases Unit,Korgialeneio-Benakeio Red Cross Hospital,Athens 11526,Greece [4]Second Department of Internal Medicine,Medical School,Democritus University of Thrace,Alexandroupolis 68100,Greece [5]Third Department of Internal Medicine and Laboratory,National and Kapodistrian University of Athens,School of Medicine,Sotiria General Hospital,Athens 11527,Greece [6]Department of Health Policy&Organization,School of Public Health,The University of Alabama at Birmingham,Birmingham,Alabama 35294,United States [7]Second Clinic of Internal Medicine,COVID-19 Department,251 Hellenic Air Force General Hospital,Athens 11525,Greece [8]Infection Control Committee,Laiko General Hospital,Athens 11527,Greece [9]Faculty of Social and Political Sciences,University of Peloponnese,Corinth 20100,Greece [10]Health Policy Institute,Athens 15123,Greece [11]Hellenic National Defence General Staff,Athens 15561,Greece

出　　处：《Infectious Medicine》2024年第4期22-29,共8页感染医学(英文)

基　　金：supported in part by an independent research grant(4900013655)from Novavax,Inc.

摘　　要：Background:To estimate the protection that coronavirus disease 2019(COVID-19)vaccine doses conferred to hospitalized patients with COVID-19 against adverse outcomes and longer length of stay during the Omicron BA.2 and BA.5 subvariant epidemics in Greece.Methods:The study was conducted from November 2022 to May 2023.Multivariable logistic and negative bi-nomial regression models were applied to estimate the association between any adverse outcomes and length of stay with the number of COVID-19 vaccine doses.Results:We studied 962 patients(median age:78 years;mean length of stay:9.2 days),of whom 847(88.0%)had≥1 comorbidity.Of these,39(4.0%)were admitted to the intensive care unit,44(4.6%)received invasive mechanical ventilation,and 110(11.4%)died in hospital.There were 184(19.1%)unvaccinated patients,125(13.0%)with one or two vaccine doses,and 653(67.9%)with≥3 doses.In multivariable analyses,patients with≥3 doses had lower odds of experiencing any adverse outcomes(adjusted odds ratio:0.57;95%confidence interval[CI]:0.37-0.86)compared with unvaccinated patients.On average,patients with one or two doses and those with≥3 had decreased length of hospital stay(−1.5 days[95%CIs:−2.6 to−0.4]and−2.8 days[95%CIs:−4.1 to−1.4],respectively)compared with unvaccinated patients.Other characteristics consistently associated with adverse outcomes and longer length of stay included older age,having three or more comorbidities compared with none,and being admitted to the hospital two or more weeks post-diagnosis.Conclusions:A history of≥3 vaccine doses conferred significant protection against any adverse outcome and longer length of stay in hospitalized patients with COVID-19.

关 键 词：COVID-19 HOSPITALIZATION Booster doses Risk factors Adverse outcomes 

分 类 号：R73[医药卫生—肿瘤]